Osborne Clarke represented Investors in $65 Million Series A Financing of Tagworks Pharmaceuticals
Osborne Clarke represented Investors in $65 Million Series A Financing of Tagworks Pharmaceuticals
Osborne Clarke, a prominent global law firm based in London, provided legal counsel to a syndicate of investors led by Gilde Healthcare and Ysios Capital, with participation from Novartis Venture Fund, New Enterprise Associates (NEA), and Lightstone Ventures. The firm advised on the successful completion of a $65 million Series A financing round for Tagworks Pharmaceuticals BV.
Tagworks Pharmaceuticals is recognized as a pioneer in Click-to-Release chemistry, a novel approach that aims to enhance the efficacy and safety of systemic therapies.
Tagworks Pharmaceuticals' innovative platform offers the capability for precise activation of antibody-drug conjugates (ADCs) and immunomodulators on the intended targets. Additionally, the platform allows for the deactivation of radiopharmaceuticals in off-target locations. The recently secured financing will provide crucial support for the development and progression of TGW101, Tagworks' leading click-cleavable ADC programme, as well as the continued advancement of the company's proprietary Click-to-Release platform.
The core deal team from Osborne Clarke, led by Partner Herke van Hulst, played a pivotal role in the transaction. The team included Senior Associate Wouter Kok and Associate Levi Schutz. Additionally, the team was complemented by partner and civil-law notary Cars Jan van Gool, Senior Associate Arlette Vrolijk, Tax partner Job van der Pol, Associate Sjoerd Waagmeester, TMC/IP partner Coen Barneveld Binkhuysen, Senior Associate Sophie den Held, GDPR Partner Joanne Zaaijer, Associate Philippe Helder, Employment, Pensions and Incentive Partner Jorgo Tsiris, and Senior Associate Wyke Schilstra.
Osborne Clarke boasts a renowned international venture capital practice and has established itself as a prominent European law firm specialising in the life science and healthcare sectors. Its sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical device companies in the market.
